Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia

Annamaria Cesarano, Pooja Gangras, Thac Duong, Francesca Albano, Francesco Di Meo, Justin Layer, Brandon Kale, Stephanie Suarez, Manuel Espinoza-Gutarra, Utpal Dave, Andrei Thomas-Tikhonenko, Monica Guzman, Timothy Shaw, Jorge Mansilla-Soto, Ly Vu, Fabiana Perna

Blood (2025) 146 (Supplement 1): 4119.

https://doi.org/10.1182/blood-2025-4119

Published: 2025

Journal Articles

Developing SEMA4A-directed CAR t cells to overcome low BCMA antigen density in multiple myeloma

Blood (2025) 146 (Supplement 1): 6100.

https://doi.org/10.1182/blood-2025-6100

Published: 2025

Journal Articles

Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).

Timothy Shaw, Melanie Mediavilla Varela, Alyssa Obermayer, Rocco English, Xiaoqing Yu, Jose Alejandro-Guevara, Jorge Mansilla-Soto, Jose Conejo-Garcia, Paulo Rodriguez, Eva Sahakian, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 5881.

https://doi.org/10.1182/blood-2025-5881

Published: 2025

Journal Articles

Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach

Agnish Dey, Jia Li, Jae H. Park, Leopold Sellner, Varsha Sundaresan, Maria Lia Palomba, Jorge Mansilla-Soto, Brigitte Senechal, Xiuyan Wang, Devanjan S Sikder, Ajeeta Dash, Isabelle Riviere, Michel Sadelain, Ganesh Mugundu

Blood (2024) 144 (Supplement 1): 7138.

https://doi.org/10.1182/blood-2024-203375

Published: 2024

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H. Park, Maria Lia Palomba, Sean M. Devlin, Yannis K. Valtis, Devanjan S Sikder, Brigitte Senechal, Xiuyan Wang, Elizabeth Cathcart, Kelly Liotta, Alina Yu, Kelsey Stocker, Honglei Zhang, Heiko Schoder, Doris Leithner, Jia Li, Leopold Sellner, Jorge Mansilla-Soto, Isabelle Riviere, Michel Sadelain

Blood (2023) 142 (Supplement 1): 892.

https://doi.org/10.1182/blood-2023-187623

Published: 2023

Journal Articles

Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering

Ashlesha Odak, Han Yuan, Judith Feucht, Vito Adrian Cantu, Jorge Mansilla-Soto, Friederike Kogel, Justin Eyquem, John Everett, Frederic D. Bushman, Christina S. Leslie, Michel Sadelain

Blood (2023) 141 (22): 2698–2712.

https://doi.org/10.1182/blood.2022018924

Published: 2023

Includes: Supplemental data

Journal Articles

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

Sascha Haubner, Jorge Mansilla-Soto, Sarah Nataraj, Friederike Kogel, Qing Chang, Elisa De Stanchina, Kathryn Fraser, Jae H Park, Xiuyan Wang, Isabelle Rivière, Michel Sadelain

Blood (2022) 140 (Supplement 1): 869–870.

https://doi.org/10.1182/blood-2022-162968

Published: 2022

Journal Articles

Overcoming Heterogeneity in AML with a Novel or-Gated Hitcar-1XX Platform

Sascha Haubner, Jorge Mansilla-Soto, Andreina Garcia Angus, Qing Chang, Elisa De Stanchina, Michel Sadelain

Blood (2022) 140 (Supplement 1): 865–866.

https://doi.org/10.1182/blood-2022-162579

Published: 2022

Journal Articles

"IF-Better" Gating: Combinatorial Targeting and Synergistic Signaling for Enhanced CAR T Cell Efficacy

Sascha Haubner, Jorge Mansilla-Soto, Sarah Nataraj, Xingyue He, Jae H Park, Xiuyan Wang, Isabelle Rivière, Michel Sadelain

Blood (2021) 138 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2021-149263

Published: 2021

Journal Articles

Targeted Integration of a CAR at a Novel Genomic Safe Harbor Directs Potent Therapeutic Outcomes

Ashlesha Odak, MS, Han Yuan, PhD, Judith Feucht, MD, Jorge Mansilla - Soto, PhD, Justin Eyquem, PhD, Christina Leslie, PhD, Michel Sadelain, MD PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-141967

Published: 2020

Journal Articles

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Blood (2018) 132 (Supplement 1): 4546.

https://doi.org/10.1182/blood-2018-99-116843

Published: 2018

Journal Articles

Systematic Combinatorial Chimeric Antigen Receptor Therapies to AML

Fabiana Perna, MD, Samuel Berman, Rajesh K Soni, PhD, Jorge Mansilla-Soto, PhD, Justin Eyquem, PhD, Mohamad Hamieh, PhD, Ronald C Hendrickson, PhD, Cameron Brennan, MD, Michel Sadelain, MD PhD

Blood (2017) 130 (Supplement 1): 856.

https://doi.org/10.1182/blood.V130.Suppl_1.856.856

Published: 2017

Journal Articles

Generation of Clonal Antigen Specific CD8αβ + Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics

Sjoukje Van Der Stegen, PhD, Raedun Clarke, PhD, Jorge Mansilla - Soto, PhD, Edwin Ortiz, Chia-Wei Chang, Jeff Sasaki, Tom Lee, PhD, Weijie Lan, PhD, Daniel Shoemaker, PhD, Isabelle Riviere, PhD, Bahram Valamehr, PhD, Michel Sadelain, MD PhD

Blood (2017) 130 (Supplement 1): 163.

https://doi.org/10.1182/blood.V130.Suppl_1.163.163

Published: 2017

Journal Articles

Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets

Fabiana Perna, MDPhD, Samuel Berman, Jorge Mansilla-Soto, PhD, Mohamad Hamieh, PhD, Rupa Juthani, MD, Rajesh Soni, PhD, Justin Eyquem, PhD, Ronald Hendrickson, PhD, Cameron Brennan, MD, Michel Sadelain, MD PhD

Blood (2016) 128 (22): 526.

https://doi.org/10.1182/blood.V128.22.526.526

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia

Developing SEMA4A-directed CAR t cells to overcome low BCMA antigen density in multiple myeloma

Dynamic changes in the bone marrow niche following CD19-targeted CAR-T cell infusion in diffuse large B cell lymphoma (DLBCL).

Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering

Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

Overcoming Heterogeneity in AML with a Novel or-Gated Hitcar-1XX Platform

"IF-Better" Gating: Combinatorial Targeting and Synergistic Signaling for Enhanced CAR T Cell Efficacy

Targeted Integration of a CAR at a Novel Genomic Safe Harbor Directs Potent Therapeutic Outcomes

Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies

Systematic Combinatorial Chimeric Antigen Receptor Therapies to AML

Generation of Clonal Antigen Specific CD8αβ + Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics

Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only